Table 3.

Biological data of peptide analogs.

Peptides a	MHC b (μmol/L)	IC50 c (μmol/L)	Therapeutic Index d	Fold e
P	5.20 ± 0.02	1.71 ± 0.07	3.04	1.0
K7D	10.4 ± 0.04	1.29 ± 0.03	8.07	2.7
K14D	5.20 ± 0.02	1.52 ± 0.05	3.42	1.1
K22D	20.81 ± 0.10	1.39 ± 0.02	14.97	4.9
K7D/K14D	20.81 ± 0.15	2.06 ± 0.01	10.10	3.3
K14D/K22D	20.81 ± 0.06	1.40 ± 0.09	14.86	4.9
K7D/K14D/K22D	81.31 ± 0.17	4.45 ± 0.19	18.27	6.0
K7D/K10D/K14D/K22D	325.20 ± 0.82	4.79 ± 0.23	67.89	22.3
K3D/K7D/K10D/K14D/K22D	>325.20	20.41 ± 0.64	31.87	10.5
K1D/K3D/K7D/K10D/K14D/K22D	>325.20	18.07 ± 0.48	35.99	11.8
L6D	10.40 ± 0.08	2.23 ± 0.10	4.67	1.5
L12D	20.81 ± 0.03	2.63 ± 0.07	7.91	2.6
L20D	20.81 ± 0.13	2.33 ± 0.06	8.93	2.9
L6D/L12D	20.81 ± 0.10	3.01 ± 0.08	6.91	2.3
L12D/L20D	81.31 ± .43	3.14 ± 0.06	25.89	8.5
L6D/L12D/L20D	162.61 ± 0.19	7.80 ± 0.26	20.85	6.9
L6D/L12D/L17D/L20D	81.31 ± 1.05	9.69 ± 0.38	8.39	2.8
L6D/L12D/L17D/L20D/L21D	>325.20	12.88 ± 0.15	50.50	16.6

^aPeptides are ordered by relative hydrophobicity;

^bHemolytic activity (minimal hemolytic concentration) was determined on human red blood cells after incubating with peptides for 1 h (hRBC); When no hemolytic activity was observed at 325.2 μmol/L, a value of 650.4 μmol/L was used for calculation of the therapeutic index;

^cAnticancer activity (IC₅₀) represents the concentration of peptides at which cell viability was reduced by 50% in comparison to untreated cells; The MTT assay was repeated in triplicate and IC₅₀ value was determined by averaging three repeated experiments;

^dTherapeutic index = MHC/IC₅₀, Larger values indicate greater anticancer specificity;

^eThe fold improvement in the therapeutic index was determined as relative to that of parent peptide P.